Contact, publication, and social network information about Harvard faculty and fellows. Harvard Catalyst Profiles
Keywords
Last Name
Institution

profileAlice Tsang Shaw, Ph.D., M.D.

TitleAssociate Professor of Medicine
InstitutionMassachusetts General Hospital
DepartmentMedicine
AddressMassachusetts General Hospital
Yawkey 7B
32 Fruit St
Boston MA 02114
Phone617/724-4000
Fax617/726-0453
vCardDownload vCard (login for email)

Collapse Research 
Collapse research activities and funding
The research activities and funding listed below are automatically derived from NIH ExPORTER and other sources, which might result in incorrect or missing items. Faculty can login to make corrections and additions.
R01CA164273     (SHAW, ALICE T)Feb 20, 2012 - Feb 28, 2022
NIH/NCI
Identification of Resistance Mechanisms to Anaplastic Lymphoma Kinase Inhibitors
Role: Co-Principal Investigator

K08CA111634     (SHAW, ALICE T)Jul 6, 2005 - Jun 30, 2010
NIH/NCI
Ras Signaling in Development and Cancer
Role: Principal Investigator

Collapse Bibliographic 
Collapse selected publications
Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
List All   |   Timeline
  1. Gainor JF, Shaw AT. Fast, Food and Ceritinib in ALK-Positive NSCLC. J Thorac Oncol. 2017 Sep; 12(9):1341-1343. PMID: 28838710.
    View in: PubMed
  2. Lin JJ, Shaw AT. Recent Advances in Targeting ROS1 in Lung Cancer. J Thorac Oncol. 2017 Aug 14. PMID: 28818606.
    View in: PubMed
  3. Gandhi L, Ou SI, Shaw AT, Barlesi F, Dingemans AC, Kim DW, Camidge DR, Hughes BGM, Yang JC, de Castro J, Crino L, Léna H, Do P, Golding S, Bordogna W, Zeaiter A, Kotb A, Gadgeel S. Efficacy of alectinib in central nervous system metastases in crizotinib-resistant ALK-positive non-small-cell lung cancer: Comparison of RECIST 1.1 and RANO-HGG criteria. Eur J Cancer. 2017 Sep; 82:27-33. PMID: 28646771.
    View in: PubMed
  4. Nishio M, Kim DW, Wu YL, Nakagawa K, Solomon BJ, Shaw AT, Hashigaki S, Ohki E, Usari T, Paolini J, Polli A, Wilner KD, Mok T. Crizotinib Versus Chemotherapy in Asian Patients with Advanced ALK-positive Non-small Cell Lung Cancer. Cancer Res Treat. 2017 Jul 06. PMID: 28701030.
    View in: PubMed
  5. Yang JC, Ou SI, De Petris L, Gadgeel S, Gandhi L, Kim DW, Barlesi F, Govindan R, Dingemans AC, Crino L, Lena H, Popat S, Ahn JS, Dansin E, Golding S, Bordogna W, Balas B, Morcos PN, Zeaiter A, Shaw AT. Pooled Systemic Efficacy and Safety Data from the Pivotal Phase II Studies (NP28673 and NP28761) of Alectinib in ALK-positive Non-Small Cell Lung Cancer. J Thorac Oncol. 2017 Jul 06. PMID: 28689043.
    View in: PubMed
  6. Shaw AT, Kim TM, Crinò L, Gridelli C, Kiura K, Liu G, Novello S, Bearz A, Gautschi O, Mok T, Nishio M, Scagliotti G, Spigel DR, Deudon S, Zheng C, Pantano S, Urban P, Massacesi C, Viraswami-Appanna K, Felip E. Ceritinib versus chemotherapy in patients with ALK-rearranged non-small-cell lung cancer previously given chemotherapy and crizotinib (ASCEND-5): a randomised, controlled, open-label, phase 3 trial. Lancet Oncol. 2017 Jul; 18(7):874-886. PMID: 28602779.
    View in: PubMed
  7. Peters S, Camidge DR, Shaw AT, Gadgeel S, Ahn JS, Kim DW, Ou SI, Pérol M, Dziadziuszko R, Rosell R, Zeaiter A, Mitry E, Golding S, Balas B, Noe J, Morcos PN, Mok T. Alectinib versus Crizotinib in Untreated ALK-Positive Non-Small-Cell Lung Cancer. N Engl J Med. 2017 08 31; 377(9):829-838. PMID: 28586279.
    View in: PubMed
  8. Soo RA, Stone ECA, Cummings KM, Jett JR, Field JK, Groen HJM, Mulshine JL, Yatabe Y, Bubendorf L, Dacic S, Rami-Porta R, Detterbeck FC, Lim E, Asamura H, Donington J, Wakelee HA, Wu YL, Higgins K, Senan S, Solomon B, Kim DW, Johnson M, Yang JCH, Sequist LV, Shaw AT, Ahn MJ, Costa DB, Patel JD, Horn L, Gettinger S, Peters S, Wynes MW, Faivre-Finn C, Rudin CM, Tsao A, Baas P, Kelly RJ, Leighl NB, Scagliotti GV, Gandara DR, Hirsch FR, Spigel DR. Scientific Advances in Thoracic Oncology 2016. J Thorac Oncol. 2017 Aug; 12(8):1183-1209. PMID: 28579481.
    View in: PubMed
  9. Dagogo-Jack I, Shaw AT. Expanding the Roster of ROS1 Inhibitors. J Clin Oncol. 2017 Aug 10; 35(23):2595-2597. PMID: 28520528.
    View in: PubMed
  10. Hsu PP, Shaw AT. Lung Cancer: A Wily Genetic Opponent. Cell. 2017 05 18; 169(5):777-779. PMID: 28525750.
    View in: PubMed
  11. Gainor JF, Shaw AT. J-ALEX: alectinib versus crizotinib in ALK-positive lung cancer. Lancet. 2017 07 01; 390(10089):3-4. PMID: 28501139.
    View in: PubMed
  12. Dagogo-Jack I, Fabrizio D, Lennerz J, Schrock AB, Young L, Mino-Kenudson M, Digumarthy SR, Heist RS, Ali SM, Miller VA, Shaw AT. Circulating Tumor DNA Identifies EGFR Coamplification as a Mechanism of Resistance to Crizotinib in a Patient with Advanced MET-Amplified Lung Adenocarcinoma. J Thorac Oncol. 2017 May 09. PMID: 28499860.
    View in: PubMed
  13. Dagogo-Jack I, Lanfranchi M, Gainor JF, Giobbie-Hurder A, Lawrence DP, Shaw AT, Sullivan RJ. A Retrospective Analysis of the Efficacy of Pembrolizumab in Melanoma Patients With Brain Metastasis. J Immunother. 2017 Apr; 40(3):108-113. PMID: 28221189.
    View in: PubMed
  14. Dagogo-Jack I, Shaw AT, Riely GJ. Optimizing treatment for patients with anaplastic lymphoma kinase-positive lung cancer. Clin Pharmacol Ther. 2017 May; 101(5):625-633. PMID: 28182271.
    View in: PubMed
  15. Drilon A, Siena S, Ou SI, Patel M, Ahn MJ, Lee J, Bauer TM, Farago AF, Wheler JJ, Liu SV, Doebele R, Giannetta L, Cerea G, Marrapese G, Schirru M, Amatu A, Bencardino K, Palmeri L, Sartore-Bianchi A, Vanzulli A, Cresta S, Damian S, Duca M, Ardini E, Li G, Christiansen J, Kowalski K, Johnson AD, Patel R, Luo D, Chow-Maneval E, Hornby Z, Multani PS, Shaw AT, De Braud FG. Safety and Antitumor Activity of the Multitargeted Pan-TRK, ROS1, and ALK Inhibitor Entrectinib: Combined Results from Two Phase I Trials (ALKA-372-001 and STARTRK-1). Cancer Discov. 2017 Apr; 7(4):400-409. PMID: 28183697.
    View in: PubMed
  16. Krall EB, Wang B, Munoz DM, Ilic N, Raghavan S, Niederst MJ, Yu K, Ruddy DA, Aguirre AJ, Kim JW, Redig AJ, Gainor JF, Williams JA, Asara JM, Doench JG, Janne PA, Shaw AT, McDonald Iii RE, Engelman JA, Stegmeier F, Schlabach MR, Hahn WC. KEAP1 loss modulates sensitivity to kinase targeted therapy in lung cancer. Elife. 2017 Feb 01; 6. PMID: 28145866.
    View in: PubMed
  17. Lin JJ, Riely GJ, Shaw AT. Targeting ALK: Precision Medicine Takes on Drug Resistance. Cancer Discov. 2017 Feb; 7(2):137-155. PMID: 28122866.
    View in: PubMed
  18. Lin JJ, Ritterhouse LL, Ali SM, Bailey M, Schrock AB, Gainor JF, Ferris LA, Mino-Kenudson M, Miller VA, Iafrate AJ, Lennerz JK, Shaw AT. ROS1 Fusions Rarely Overlap with Other Oncogenic Drivers in Non-Small Cell Lung Cancer. J Thorac Oncol. 2017 May; 12(5):872-877. PMID: 28088512.
    View in: PubMed
  19. Dagogo-Jack I, Saltos A, Shaw AT, Gray JE. Pathology Issues in Thoracic Oncology: Histologic Characterization and Tissue/Plasma Genotyping May Resolve Diagnostic Dilemmas. Am Soc Clin Oncol Educ Book. 2017; 37:619-629. PMID: 28561671.
    View in: PubMed
  20. Lin JJ, Shaw AT. Raising the bar on first-line immunotherapy in lung cancer. Lancet Oncol. 2017 Jan; 18(1):2-3. PMID: 27932066.
    View in: PubMed
  21. Gettinger SN, Bazhenova LA, Langer CJ, Salgia R, Gold KA, Rosell R, Shaw AT, Weiss GJ, Tugnait M, Narasimhan NI, Dorer DJ, Kerstein D, Rivera VM, Clackson T, Haluska FG, Camidge DR. Activity and safety of brigatinib in ALK-rearranged non-small-cell lung cancer and other malignancies: a single-arm, open-label, phase 1/2 trial. Lancet Oncol. 2016 Dec; 17(12):1683-1696. PMID: 27836716.
    View in: PubMed
  22. Gadgeel SM, Shaw AT, Govindan R, Gandhi L, Socinski MA, Camidge DR, De Petris L, Kim DW, Chiappori A, Moro-Sibilot DL, Duruisseaux M, Crino L, De Pas T, Dansin E, Tessmer A, Yang JC, Han JY, Bordogna W, Golding S, Zeaiter A, Ou SI. Pooled Analysis of CNS Response to Alectinib in Two Studies of Pretreated Patients With ALK-Positive Non-Small-Cell Lung Cancer. J Clin Oncol. 2016 Dec; 34(34):4079-4085. PMID: 27863201.
    View in: PubMed
  23. Shaw AT, Spigel DR, Tan DS, Kim DW, Mehra R, Orlov S, Park K, Yu CJ, Mok T, Nishio M, Scagliotti G, Sutradhar S, Cesic D, Felip E. MINI01.01: Whole Body and Intracranial Efficacy of Ceritinib in ALK-inhibitor Naïve Patients with ALK+ NSCLC and Brain Metastases: Results of ASCEND 1 and 3: Topic: Medical Oncology. J Thorac Oncol. 2016 Nov; 11(11S):S256. PMID: 27969450.
    View in: PubMed
  24. Dagogo-Jack I, Shaw AT. Crizotinib resistance: implications for therapeutic strategies. Ann Oncol. 2016 Sep; 27 Suppl 3:iii42-iii50. PMID: 27573756; PMCID: PMC5003168 [Available on 09/01/17].
  25. Temel JS, Shaw AT, Greer JA. Challenge of Prognostic Uncertainty in the Modern Era of Cancer Therapeutics. J Clin Oncol. 2016 Aug 22. PMID: 27551112.
    View in: PubMed
  26. Campo M, Gerber D, Gainor JF, Heist RS, Temel JS, Shaw AT, Fidias P, Muzikansky A, Engelman JA, Sequist LV. Acquired Resistance to First-Line Afatinib and the Challenges of Prearranged Progression Biopsies. J Thorac Oncol. 2016 Nov; 11(11):2022-2026. PMID: 27553514.
    View in: PubMed
  27. Lin JJ, Kennedy E, Sequist LV, Brastianos PK, Goodwin KE, Stevens S, Wanat AC, Stober LL, Digumarthy SR, Engelman JA, Shaw AT, Gainor JF. Clinical Activity of Alectinib in Advanced RET-Rearranged Non-Small Cell Lung Cancer. J Thorac Oncol. 2016 Nov; 11(11):2027-2032. PMID: 27544060.
    View in: PubMed
  28. Lin JJ, Shaw AT. Differential Sensitivity to Crizotinib: Does EML4-ALK Fusion Variant Matter? J Clin Oncol. 2016 Oct 01; 34(28):3363-5. PMID: 27458283.
    View in: PubMed
  29. Gainor JF, Dardaei L, Yoda S, Friboulet L, Leshchiner I, Katayama R, Dagogo-Jack I, Gadgeel S, Schultz K, Singh M, Chin E, Parks M, Lee D, DiCecca RH, Lockerman E, Huynh T, Logan J, Ritterhouse LL, Le LP, Muniappan A, Digumarthy S, Channick C, Keyes C, Getz G, Dias-Santagata D, Heist RS, Lennerz J, Sequist LV, Benes CH, Iafrate AJ, Mino-Kenudson M, Engelman JA, Shaw AT. Molecular Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in ALK-Rearranged Lung Cancer. Cancer Discov. 2016 Oct; 6(10):1118-1133. PMID: 27432227.
    View in: PubMed
  30. Crinò L, Ahn MJ, De Marinis F, Groen HJ, Wakelee H, Hida T, Mok T, Spigel D, Felip E, Nishio M, Scagliotti G, Branle F, Emeremni C, Quadrigli M, Zhang J, Shaw AT. Multicenter Phase II Study of Whole-Body and Intracranial Activity With Ceritinib in Patients With ALK-Rearranged Non-Small-Cell Lung Cancer Previously Treated With Chemotherapy and Crizotinib: Results From ASCEND-2. J Clin Oncol. 2016 Aug 20; 34(24):2866-73. PMID: 27432917.
    View in: PubMed
  31. Waqar SN, Bonomi PD, Govindan R, Hirsch FR, Riely GJ, Papadimitrakopoulou V, Kazandjian D, Khozin S, Larkins E, Dickson DJ, Malik S, Horn L, Ferris A, Shaw AT, Jänne PA, Mok TS, Herbst R, Keegan P, Pazdur R, Blumenthal GM. Clinician Perspectives on Current Issues in Lung Cancer Drug Development. J Thorac Oncol. 2016 Sep; 11(9):1387-96. PMID: 27401214.
    View in: PubMed
  32. Lin JJ, Shaw AT. Resisting Resistance: Targeted Therapies in Lung Cancer. Trends Cancer. 2016 Jul; 2(7):350-364. PMID: 27819059.
    View in: PubMed
  33. Campo M, Al-Halabi H, Khandekar M, Shaw AT, Sequist LV, Willers H. Integration of Stereotactic Body Radiation Therapy With Tyrosine Kinase Inhibitors in Stage IV Oncogene-Driven Lung Cancer. Oncologist. 2016 Aug; 21(8):964-73. PMID: 27354669; PMCID: PMC4978553 [Available on 08/01/17].
  34. Heist RS, Sequist LV, Borger D, Gainor JF, Arellano RS, Le LP, Dias-Santagata D, Clark JW, Engelman JA, Shaw AT, Iafrate AJ. Acquired Resistance to Crizotinib in NSCLC with MET Exon 14 Skipping. J Thorac Oncol. 2016 Aug; 11(8):1242-5. PMID: 27343442.
    View in: PubMed
  35. Dagogo-Jack I, Gainor JF, Porter RL, Schultz KR, Solomon BJ, Stevens S, Azzoli CG, Sequist LV, Lennes IT, Shaw AT. Clinicopathologic Features of NSCLC Diagnosed During Pregnancy or the Peripartum Period in the Era of Molecular Genotyping. J Thorac Oncol. 2016 Sep; 11(9):1522-8. PMID: 27296107; PMCID: PMC5002360 [Available on 09/01/17].
  36. Jänne PA, Kim G, Shaw AT, Sridhara R, Pazdur R, McKee AE. Dose Finding of Small-Molecule Oncology Drugs: Optimization throughout the Development Life Cycle. Clin Cancer Res. 2016 Jun 01; 22(11):2613-7. PMID: 27250931.
    View in: PubMed
  37. Dagogo-Jack I, Shaw AT. Screening for ALK Rearrangements in Lung Cancer: Time for a New Generation of Diagnostics? Oncologist. 2016 Jun; 21(6):662-3. PMID: 27245570; PMCID: PMC4912373.
  38. Gainor JF, Shaw AT, Sequist LV, Fu X, Azzoli CG, Piotrowska Z, Huynh TG, Zhao L, Fulton L, Schultz KR, Howe E, Farago AF, Sullivan RJ, Stone JR, Digumarthy S, Moran T, Hata AN, Yagi Y, Yeap BY, Engelman JA, Mino-Kenudson M. EGFR Mutations and ALK Rearrangements Are Associated with Low Response Rates to PD-1 Pathway Blockade in Non-Small Cell Lung Cancer: A Retrospective Analysis. Clin Cancer Res. 2016 Sep 15; 22(18):4585-93. PMID: 27225694; PMCID: PMC5026567 [Available on 09/15/17].
  39. Shaw AT, Engelman JA. Crizotinib Resensitization by Compound Mutation. N Engl J Med. 2016 May 05; 374(18):1790-1. PMID: 27144862.
    View in: PubMed
  40. Tan D, Liu G, Kim DW, Thomas M, Felip E, Signorovitch J, Zhang J, Szczudlo T, Shaw AT. 178P: Continuation of ceritinib beyond disease progression is associated with prolonged post-progression survival (PPS) in ALK+ NSCLC. J Thorac Oncol. 2016 Apr; 11(4 Suppl):S134-5. PMID: 27198316.
    View in: PubMed
  41. Felip E, Crinò L, Kim DW, Spigel DR, Nishio M, Mok T, Scagliotti G, Cesic D, Sutradhar S, Shaw AT. 141PD: Whole body and intracranial efficacy of ceritinib in patients (pts) with crizotinib (CRZ) pretreated, ALK-rearranged (ALK+) non-small cell lung cancer (NSCLC) and baseline brain metastases (BM): Results from ASCEND-1 and ASCEND-2 trials. J Thorac Oncol. 2016 Apr; 11(4 Suppl):S118-9. PMID: 27198279.
    View in: PubMed
  42. Rosell R, Gettinger SN, Bazhenova LA, Langer CJ, Salgia R, Shaw AT, Narasimhan NI, Dorer DJ, Kerstein D, Camidge DR. 1330: Brigatinib efficacy and safety in patients (Pts) with anaplastic lymphoma kinase (ALK)-positive (ALK+) non-small cell lung cancer (NSCLC) in a phase 1/2 trial. J Thorac Oncol. 2016 Apr; 11(4 Suppl):S114. PMID: 27198273.
    View in: PubMed
  43. Sequist LV, Piotrowska Z, Niederst MJ, Heist RS, Digumarthy S, Shaw AT, Engelman JA. Osimertinib Responses After Disease Progression in Patients Who Had Been Receiving Rociletinib. JAMA Oncol. 2016 Apr; 2(4):541-3. PMID: 26720284.
    View in: PubMed
  44. Gainor JF, Niederst MJ, Lennerz JK, Dagogo-Jack I, Stevens S, Shaw AT, Sequist LV, Engelman JA. Dramatic Response to Combination Erlotinib and Crizotinib in a Patient with Advanced, EGFR-Mutant Lung Cancer Harboring De Novo MET Amplification. J Thorac Oncol. 2016 Jul; 11(7):e83-5. PMID: 26988570.
    View in: PubMed
  45. Kim DW, Mehra R, Tan DS, Felip E, Chow LQ, Camidge DR, Vansteenkiste J, Sharma S, De Pas T, Riely GJ, Solomon BJ, Wolf J, Thomas M, Schuler M, Liu G, Santoro A, Sutradhar S, Li S, Szczudlo T, Yovine A, Shaw AT. Activity and safety of ceritinib in patients with ALK-rearranged non-small-cell lung cancer (ASCEND-1): updated results from the multicentre, open-label, phase 1 trial. Lancet Oncol. 2016 Apr; 17(4):452-63. PMID: 26973324.
    View in: PubMed
  46. Jänne PA, Shaw AT, Camidge DR, Giaccone G, Shreeve SM, Tang Y, Goldberg Z, Martini JF, Xu H, James LP, Solomon BJ. Combined Pan-HER and ALK/ROS1/MET Inhibition with Dacomitinib and Crizotinib in Advanced Non-Small Cell Lung Cancer: Results of a Phase I Study. J Thorac Oncol. 2016 May; 11(5):737-47. PMID: 26899759.
    View in: PubMed
  47. Shaw AT, Friboulet L, Leshchiner I, Gainor JF, Bergqvist S, Brooun A, Burke BJ, Deng YL, Liu W, Dardaei L, Frias RL, Schultz KR, Logan J, James LP, Smeal T, Timofeevski S, Katayama R, Iafrate AJ, Le L, McTigue M, Getz G, Johnson TW, Engelman JA. Resensitization to Crizotinib by the Lorlatinib ALK Resistance Mutation L1198F. N Engl J Med. 2016 Jan 07; 374(1):54-61. PMID: 26698910; PMCID: PMC4773904.
  48. Shaw AT, Gandhi L, Gadgeel S, Riely GJ, Cetnar J, West H, Camidge DR, Socinski MA, Chiappori A, Mekhail T, Chao BH, Borghaei H, Gold KA, Zeaiter A, Bordogna W, Balas B, Puig O, Henschel V, Ou SI. Alectinib in ALK-positive, crizotinib-resistant, non-small-cell lung cancer: a single-group, multicentre, phase 2 trial. Lancet Oncol. 2016 Feb; 17(2):234-242. PMID: 26708155; PMCID: PMC4752892 [Available on 02/01/17].
  49. Gainor JF, Chi AS, Logan J, Hu R, Oh KS, Brastianos PK, Shih HA, Shaw AT. Alectinib Dose Escalation Reinduces Central Nervous System Responses in Patients with Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer Relapsing on Standard Dose Alectinib. J Thorac Oncol. 2016 Feb; 11(2):256-60. PMID: 26845119; PMCID: PMC4743545 [Available on 02/01/17].
  50. Katayama R, Sakashita T, Yanagitani N, Ninomiya H, Horiike A, Friboulet L, Gainor JF, Motoi N, Dobashi A, Sakata S, Tambo Y, Kitazono S, Sato S, Koike S, John Iafrate A, Mino-Kenudson M, Ishikawa Y, Shaw AT, Engelman JA, Takeuchi K, Nishio M, Fujita N. P-glycoprotein Mediates Ceritinib Resistance in Anaplastic Lymphoma Kinase-rearranged Non-small Cell Lung Cancer. EBioMedicine. 2016 Jan; 3:54-66. PMID: 26870817; PMCID: PMC4739423.
  51. Farago AF, Le LP, Zheng Z, Muzikansky A, Drilon A, Patel M, Bauer TM, Liu SV, Ou SH, Jackman D, Costa DB, Multani PS, Li GG, Hornby Z, Chow-Maneval E, Luo D, Lim JE, Iafrate AJ, Shaw AT. Durable Clinical Response to Entrectinib in NTRK1-Rearranged Non-Small Cell Lung Cancer. J Thorac Oncol. 2015 Dec; 10(12):1670-4. PMID: 26565381; PMCID: PMC4643748.
  52. Richly H, Kim TM, Schuler M, Kim DW, Harrison SJ, Shaw AT, Boral AL, Yovine A, Solomon B. Ceritinib in patients with advanced anaplastic lymphoma kinase-rearranged anaplastic large-cell lymphoma. Blood. 2015 Sep 03; 126(10):1257-8. PMID: 26337354; PMCID: PMC4559938.
  53. Zou HY, Friboulet L, Kodack DP, Engstrom LD, Li Q, West M, Tang RW, Wang H, Tsaparikos K, Wang J, Timofeevski S, Katayama R, Dinh DM, Lam H, Lam JL, Yamazaki S, Hu W, Patel B, Bezwada D, Frias RL, Lifshits E, Mahmood S, Gainor JF, Affolter T, Lappin PB, Gukasyan H, Lee N, Deng S, Jain RK, Johnson TW, Shaw AT, Fantin VR, Smeal T. PF-06463922, an ALK/ROS1 Inhibitor, Overcomes Resistance to First and Second Generation ALK Inhibitors in Preclinical Models. Cancer Cell. 2015 Jul 13; 28(1):70-81. PMID: 26144315; PMCID: PMC4504786 [Available on 07/13/16].
  54. Jänne PA, Smith I, McWalter G, Mann H, Dougherty B, Walker J, Orr MC, Hodgson DR, Shaw AT, Pereira JR, Jeannin G, Vansteenkiste J, Barrios CH, Franke FA, Crinò L, Smith P. Impact of KRAS codon subtypes from a randomised phase II trial of selumetinib plus docetaxel in KRAS mutant advanced non-small-cell lung cancer. Br J Cancer. 2015 Jul 14; 113(2):199-203. PMID: 26125448; PMCID: PMC4506393.
  55. Katayama R, Lovly CM, Shaw AT. Therapeutic targeting of anaplastic lymphoma kinase in lung cancer: a paradigm for precision cancer medicine. Clin Cancer Res. 2015 May 15; 21(10):2227-35. PMID: 25979929; PMCID: PMC4435823 [Available on 05/15/16].
  56. Shaw AT. Combining inhibitors of ALK and ROS1 with other agents for the treatment of non-small cell lung cancer. Clin Adv Hematol Oncol. 2015 May; 13(5):282-4. PMID: 26352769.
    View in: PubMed
  57. Piotrowska Z, Niederst MJ, Karlovich CA, Wakelee HA, Neal JW, Mino-Kenudson M, Fulton L, Hata AN, Lockerman EL, Kalsy A, Digumarthy S, Muzikansky A, Raponi M, Garcia AR, Mulvey HE, Parks MK, DiCecca RH, Dias-Santagata D, Iafrate AJ, Shaw AT, Allen AR, Engelman JA, Sequist LV. Heterogeneity Underlies the Emergence of EGFRT790 Wild-Type Clones Following Treatment of T790M-Positive Cancers with a Third-Generation EGFR Inhibitor. Cancer Discov. 2015 Jul; 5(7):713-22. PMID: 25934077; PMCID: PMC4497836 [Available on 01/01/16].
  58. Schnell P, Bartlett CH, Solomon BJ, Tassell V, Shaw AT, de Pas T, Lee SH, Lee GK, Tanaka K, Tan W, Tang Y, Wilner KD, Safferman A, Han JY. Complex renal cysts associated with crizotinib treatment. Cancer Med. 2015 Jun; 4(6):887-96. PMID: 25756473; PMCID: PMC4472211.
  59. Shuster M, Morley K, Logan J, Sequist LV, Shaw A, Fidias P, Kroshinsky D. Lipodermatosclerosis secondary to pemetrexed use. J Thorac Oncol. 2015 Mar; 10(3):e11-2. PMID: 25695225.
    View in: PubMed
  60. Yu HA, Sima CS, Shen R, Kass S, Gainor J, Shaw A, Hames M, Iams W, Aston J, Lovly CM, Horn L, Lydon C, Oxnard GR, Kris MG, Ladanyi M, Riely GJ. Prognostic impact of KRAS mutation subtypes in 677 patients with metastatic lung adenocarcinomas. J Thorac Oncol. 2015 Mar; 10(3):431-7. PMID: 25415430; PMCID: PMC4479120.
  61. Gainor JF, Tan DS, De Pas T, Solomon BJ, Ahmad A, Lazzari C, de Marinis F, Spitaleri G, Schultz K, Friboulet L, Yeap BY, Engelman JA, Shaw AT. Progression-Free and Overall Survival in ALK-Positive NSCLC Patients Treated with Sequential Crizotinib and Ceritinib. Clin Cancer Res. 2015 Jun 15; 21(12):2745-52. PMID: 25724526; PMCID: PMC4470734 [Available on 06/15/16].
  62. Shaw AT, Solomon BJ. Crizotinib in ROS1-rearranged non-small-cell lung cancer. N Engl J Med. 2015 Feb 12; 372(7):683-4. PMID: 25671264.
    View in: PubMed
  63. Gainor JF, Sherman CA, Willoughby K, Logan J, Kennedy E, Brastianos PK, Chi AS, Shaw AT. Alectinib salvages CNS relapses in ALK-positive lung cancer patients previously treated with crizotinib and ceritinib. J Thorac Oncol. 2015 Feb; 10(2):232-6. PMID: 25526238; PMCID: PMC4304931 [Available on 02/01/16].
  64. Costa DB, Shaw AT, Ou SH, Solomon BJ, Riely GJ, Ahn MJ, Zhou C, Shreeve SM, Selaru P, Polli A, Schnell P, Wilner KD, Wiltshire R, Camidge DR, Crinò L. Clinical Experience With Crizotinib in Patients With Advanced ALK-Rearranged Non-Small-Cell Lung Cancer and Brain Metastases. J Clin Oncol. 2015 Jun 10; 33(17):1881-8. PMID: 25624436; PMCID: PMC4451171 [Available on 06/10/16].
  65. Heist RS, Duda DG, Sahani DV, Ancukiewicz M, Fidias P, Sequist LV, Temel JS, Shaw AT, Pennell NA, Neal JW, Gandhi L, Lynch TJ, Engelman JA, Jain RK. Improved tumor vascularization after anti-VEGF therapy with carboplatin and nab-paclitaxel associates with survival in lung cancer. Proc Natl Acad Sci U S A. 2015 Feb 03; 112(5):1547-52. PMID: 25605928; PMCID: PMC4321320.
  66. Morgensztern D, Campo MJ, Dahlberg SE, Doebele RC, Garon E, Gerber DE, Goldberg SB, Hammerman PS, Heist RS, Hensing T, Horn L, Ramalingam SS, Rudin CM, Salgia R, Sequist LV, Shaw AT, Simon GR, Somaiah N, Spigel DR, Wrangle J, Johnson D, Herbst RS, Bunn P, Govindan R. Molecularly targeted therapies in non-small-cell lung cancer annual update 2014. J Thorac Oncol. 2015 Jan; 10(1 Suppl 1):S1-63. PMID: 25535693; PMCID: PMC4346098 [Available on 01/01/16].
  67. Neal JW, Gainor JF, Shaw AT. Developing biomarker-specific end points in lung cancer clinical trials. Nat Rev Clin Oncol. 2015 Mar; 12(3):135-46. PMID: 25533947.
    View in: PubMed
  68. Crystal AS, Shaw AT, Sequist LV, Friboulet L, Niederst MJ, Lockerman EL, Frias RL, Gainor JF, Amzallag A, Greninger P, Lee D, Kalsy A, Gomez-Caraballo M, Elamine L, Howe E, Hur W, Lifshits E, Robinson HE, Katayama R, Faber AC, Awad MM, Ramaswamy S, Mino-Kenudson M, Iafrate AJ, Benes CH, Engelman JA. Patient-derived models of acquired resistance can identify effective drug combinations for cancer. Science. 2014 Dec 19; 346(6216):1480-6. PMID: 25394791; PMCID: PMC4388482.
  69. Blackhall F, Kim DW, Besse B, Nokihara H, Han JY, Wilner KD, Reisman A, Iyer S, Hirsh V, Shaw AT. Patient-reported outcomes and quality of life in PROFILE 1007: a randomized trial of crizotinib compared with chemotherapy in previously treated patients with ALK-positive advanced non-small-cell lung cancer. J Thorac Oncol. 2014 Nov; 9(11):1625-33. PMID: 25436797.
    View in: PubMed
  70. Awad MM, Lax TP, Slawski BR, Shaw AT. Successful desensitization of two patients with ALK-positive lung cancer and hypersensitivity to crizotinib. J Thorac Oncol. 2014 Nov; 9(11):1726-8. PMID: 25436807.
    View in: PubMed
  71. Katayama R, Kobayashi Y, Friboulet L, Lockerman EL, Koike S, Shaw AT, Engelman JA, Fujita N. Cabozantinib overcomes crizotinib resistance in ROS1 fusion-positive cancer. Clin Cancer Res. 2015 Jan 01; 21(1):166-74. PMID: 25351743; PMCID: PMC4286456.
  72. Shaw AT, Ou SH, Bang YJ, Camidge DR, Solomon BJ, Salgia R, Riely GJ, Varella-Garcia M, Shapiro GI, Costa DB, Doebele RC, Le LP, Zheng Z, Tan W, Stephenson P, Shreeve SM, Tye LM, Christensen JG, Wilner KD, Clark JW, Iafrate AJ. Crizotinib in ROS1-rearranged non-small-cell lung cancer. N Engl J Med. 2014 Nov 20; 371(21):1963-71. PMID: 25264305; PMCID: PMC4264527.
  73. Katayama R, Friboulet L, Koike S, Lockerman EL, Khan TM, Gainor JF, Iafrate AJ, Takeuchi K, Taiji M, Okuno Y, Fujita N, Engelman JA, Shaw AT. Two novel ALK mutations mediate acquired resistance to the next-generation ALK inhibitor alectinib. Clin Cancer Res. 2014 Nov 15; 20(22):5686-96. PMID: 25228534; PMCID: PMC4233168.
  74. Azzoli CG, Engelman J, Fidias P, Gainor JF, Heist RS, Lamont EB, Lennes IT, Rosovsky RP, Sequist LV, Shaw AT, Temel JS. Genotyping lung cancer is an investment in the future. J Clin Oncol. 2014 Nov 01; 32(31):3576-7. PMID: 25199750.
    View in: PubMed
  75. Mak KS, Gainor JF, Niemierko A, Oh KS, Willers H, Choi NC, Loeffler JS, Sequist LV, Shaw AT, Shih HA. Significance of targeted therapy and genetic alterations in EGFR, ALK, or KRAS on survival in patients with non-small cell lung cancer treated with radiotherapy for brain metastases. Neuro Oncol. 2015 Feb; 17(2):296-302. PMID: 25053852; PMCID: PMC4288518.
  76. Awad MM, Shaw AT. ALK inhibitors in non-small cell lung cancer: crizotinib and beyond. Clin Adv Hematol Oncol. 2014 Jul; 12(7):429-39. PMID: 25322323; PMCID: PMC4215402.
  77. Shaw AT, Engelman JA. Ceritinib in ALK-rearranged non-small-cell lung cancer. N Engl J Med. 2014 Jun 26; 370(26):2537-9. PMID: 24963575.
    View in: PubMed
  78. Lovly CM, Shaw AT. Molecular pathways: resistance to kinase inhibitors and implications for therapeutic strategies. Clin Cancer Res. 2014 May 01; 20(9):2249-56. PMID: 24789032; PMCID: PMC4029617.
  79. Friboulet L, Li N, Katayama R, Lee CC, Gainor JF, Crystal AS, Michellys PY, Awad MM, Yanagitani N, Kim S, Pferdekamper AC, Li J, Kasibhatla S, Sun F, Sun X, Hua S, McNamara P, Mahmood S, Lockerman EL, Fujita N, Nishio M, Harris JL, Shaw AT, Engelman JA. The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer. Cancer Discov. 2014 Jun; 4(6):662-673. PMID: 24675041; PMCID: PMC4068971.
  80. Shaw AT, Kim DW, Mehra R, Tan DS, Felip E, Chow LQ, Camidge DR, Vansteenkiste J, Sharma S, De Pas T, Riely GJ, Solomon BJ, Wolf J, Thomas M, Schuler M, Liu G, Santoro A, Lau YY, Goldwasser M, Boral AL, Engelman JA. Ceritinib in ALK-rearranged non-small-cell lung cancer. N Engl J Med. 2014 Mar 27; 370(13):1189-97. PMID: 24670165; PMCID: PMC4079055.
  81. Gainor JF, Ou SH, Logan J, Borges LF, Shaw AT. The central nervous system as a sanctuary site in ALK-positive non-small-cell lung cancer. J Thorac Oncol. 2013 Dec; 8(12):1570-3. PMID: 24389440.
    View in: PubMed
  82. Shaw AT, Hsu PP, Awad MM, Engelman JA. Tyrosine kinase gene rearrangements in epithelial malignancies. Nat Rev Cancer. 2013 Nov; 13(11):772-87. PMID: 24132104; PMCID: PMC3902129.
  83. Gainor JF, Shaw AT. Emerging paradigms in the development of resistance to tyrosine kinase inhibitors in lung cancer. J Clin Oncol. 2013 Nov 01; 31(31):3987-96. PMID: 24101047; PMCID: PMC3805932.
  84. Solomon B, Wilner KD, Shaw AT. Current status of targeted therapy for anaplastic lymphoma kinase-rearranged non-small cell lung cancer. Clin Pharmacol Ther. 2014 Jan; 95(1):15-23. PMID: 24091716.
    View in: PubMed
  85. Awad MM, Engelman JA, Shaw AT. Acquired resistance to crizotinib from a mutation in CD74-ROS1. N Engl J Med. 2013 Sep 19; 369(12):1173. PMID: 24047072.
    View in: PubMed
  86. Gainor JF, Shaw AT. Novel targets in non-small cell lung cancer: ROS1 and RET fusions. Oncologist. 2013; 18(7):865-75. PMID: 23814043; PMCID: PMC3720641.
  87. Awad MM, Katayama R, McTigue M, Liu W, Deng YL, Brooun A, Friboulet L, Huang D, Falk MD, Timofeevski S, Wilner KD, Lockerman EL, Khan TM, Mahmood S, Gainor JF, Digumarthy SR, Stone JR, Mino-Kenudson M, Christensen JG, Iafrate AJ, Engelman JA, Shaw AT. Acquired resistance to crizotinib from a mutation in CD74-ROS1. N Engl J Med. 2013 Jun 20; 368(25):2395-401. PMID: 23724914; PMCID: PMC3878821.
  88. Gainor JF, Shaw AT. The new kid on the block: RET in lung cancer. Cancer Discov. 2013 Jun; 3(6):604-6. PMID: 23749525.
    View in: PubMed
  89. Shaw AT, Kim DW, Nakagawa K, Seto T, Crinó L, Ahn MJ, De Pas T, Besse B, Solomon BJ, Blackhall F, Wu YL, Thomas M, O'Byrne KJ, Moro-Sibilot D, Camidge DR, Mok T, Hirsh V, Riely GJ, Iyer S, Tassell V, Polli A, Wilner KD, Jänne PA. Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N Engl J Med. 2013 Jun 20; 368(25):2385-94. PMID: 23724913.
    View in: PubMed
  90. Gainor JF, Varghese AM, Ou SH, Kabraji S, Awad MM, Katayama R, Pawlak A, Mino-Kenudson M, Yeap BY, Riely GJ, Iafrate AJ, Arcila ME, Ladanyi M, Engelman JA, Dias-Santagata D, Shaw AT. ALK rearrangements are mutually exclusive with mutations in EGFR or KRAS: an analysis of 1,683 patients with non-small cell lung cancer. Clin Cancer Res. 2013 Aug 01; 19(15):4273-81. PMID: 23729361; PMCID: PMC3874127.
  91. Ozkumur E, Shah AM, Ciciliano JC, Emmink BL, Miyamoto DT, Brachtel E, Yu M, Chen PI, Morgan B, Trautwein J, Kimura A, Sengupta S, Stott SL, Karabacak NM, Barber TA, Walsh JR, Smith K, Spuhler PS, Sullivan JP, Lee RJ, Ting DT, Luo X, Shaw AT, Bardia A, Sequist LV, Louis DN, Maheswaran S, Kapur R, Haber DA, Toner M. Inertial focusing for tumor antigen-dependent and -independent sorting of rare circulating tumor cells. Sci Transl Med. 2013 Apr 03; 5(179):179ra47. PMID: 23552373; PMCID: PMC3760275.
  92. Sang J, Acquaviva J, Friedland JC, Smith DL, Sequeira M, Zhang C, Jiang Q, Xue L, Lovly CM, Jimenez JP, Shaw AT, Doebele RC, He S, Bates RC, Camidge DR, Morris SW, El-Hariry I, Proia DA. Targeted inhibition of the molecular chaperone Hsp90 overcomes ALK inhibitor resistance in non-small cell lung cancer. Cancer Discov. 2013 Apr; 3(4):430-43. PMID: 23533265; PMCID: PMC4086149.
  93. Shaw AT, Engelman JA. ALK in lung cancer: past, present, and future. J Clin Oncol. 2013 Mar 10; 31(8):1105-11. PMID: 23401436; PMCID: PMC4209068.
  94. Kwak EL, Clark JW, Shaw AT. Targeted inhibition in tumors with ALK dependency. Lung Cancer (Auckl). 2013; 4:1-8. PMID: 28210129.
    View in: PubMed
  95. Jänne PA, Shaw AT, Pereira JR, Jeannin G, Vansteenkiste J, Barrios C, Franke FA, Grinsted L, Zazulina V, Smith P, Smith I, Crinò L. Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: a randomised, multicentre, placebo-controlled, phase 2 study. Lancet Oncol. 2013 Jan; 14(1):38-47. PMID: 23200175.
    View in: PubMed
  96. Goldberg SB, Supko JG, Neal JW, Muzikansky A, Digumarthy S, Fidias P, Temel JS, Heist RS, Shaw AT, McCarthy PO, Lynch TJ, Sharma S, Settleman JE, Sequist LV. A phase I study of erlotinib and hydroxychloroquine in advanced non-small-cell lung cancer. J Thorac Oncol. 2012 Oct; 7(10):1602-8. PMID: 22878749; PMCID: PMC3791327.
  97. Camidge DR, Bang YJ, Kwak EL, Iafrate AJ, Varella-Garcia M, Fox SB, Riely GJ, Solomon B, Ou SH, Kim DW, Salgia R, Fidias P, Engelman JA, Gandhi L, Jänne PA, Costa DB, Shapiro GI, Lorusso P, Ruffner K, Stephenson P, Tang Y, Wilner K, Clark JW, Shaw AT. Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study. Lancet Oncol. 2012 Oct; 13(10):1011-9. PMID: 22954507; PMCID: PMC3936578.
  98. Crystal AS, Shaw AT. Variants on a theme: a biomarker of crizotinib response in ALK-positive non-small cell lung cancer? Clin Cancer Res. 2012 Sep 01; 18(17):4479-81. PMID: 22912388.
    View in: PubMed
  99. Shaw AT, Varghese AM, Solomon BJ, Costa DB, Novello S, Mino-Kenudson M, Awad MM, Engelman JA, Riely GJ, Monica V, Yeap BY, Scagliotti GV. Pemetrexed-based chemotherapy in patients with advanced, ALK-positive non-small cell lung cancer. Ann Oncol. 2013 Jan; 24(1):59-66. PMID: 22887466; PMCID: PMC3525134.
  100. Ramalingam SS, Shaw AT. Hypogonadism related to crizotinib therapy: implications for patient care. Cancer. 2012 Nov 01; 118(21):E1-2. PMID: 22487894.
    View in: PubMed
  101. Katayama R, Shaw AT, Khan TM, Mino-Kenudson M, Solomon BJ, Halmos B, Jessop NA, Wain JC, Yeo AT, Benes C, Drew L, Saeh JC, Crosby K, Sequist LV, Iafrate AJ, Engelman JA. Mechanisms of acquired crizotinib resistance in ALK-rearranged lung Cancers. Sci Transl Med. 2012 Feb 08; 4(120):120ra17. PMID: 22277784; PMCID: PMC3385512.
  102. Bergethon K, Shaw AT, Ou SH, Katayama R, Lovly CM, McDonald NT, Massion PP, Siwak-Tapp C, Gonzalez A, Fang R, Mark EJ, Batten JM, Chen H, Wilner KD, Kwak EL, Clark JW, Carbone DP, Ji H, Engelman JA, Mino-Kenudson M, Pao W, Iafrate AJ. ROS1 rearrangements define a unique molecular class of lung cancers. J Clin Oncol. 2012 Mar 10; 30(8):863-70. PMID: 22215748; PMCID: PMC3295572.
  103. Solomon B, Shaw AT. Are anaplastic lymphoma kinase gene rearrangements in non-small cell lung cancer prognostic, predictive, or both? J Thorac Oncol. 2012 Jan; 7(1):5-7. PMID: 22173659.
    View in: PubMed
  104. Shaw AT, Yasothan U, Kirkpatrick P. Crizotinib. Nat Rev Drug Discov. 2011 Dec 01; 10(12):897-8. PMID: 22129984.
    View in: PubMed
  105. Shaw AT, Solomon B, Kenudson MM. Crizotinib and testing for ALK. J Natl Compr Canc Netw. 2011 Dec; 9(12):1335-41. PMID: 22157554.
    View in: PubMed
  106. Sequist LV, Heist RS, Shaw AT, Fidias P, Rosovsky R, Temel JS, Lennes IT, Digumarthy S, Waltman BA, Bast E, Tammireddy S, Morrissey L, Muzikansky A, Goldberg SB, Gainor J, Channick CL, Wain JC, Gaissert H, Donahue DM, Muniappan A, Wright C, Willers H, Mathisen DJ, Choi NC, Baselga J, Lynch TJ, Ellisen LW, Mino-Kenudson M, Lanuti M, Borger DR, Iafrate AJ, Engelman JA, Dias-Santagata D. Implementing multiplexed genotyping of non-small-cell lung cancers into routine clinical practice. Ann Oncol. 2011 Dec; 22(12):2616-24. PMID: 22071650; PMCID: PMC3493130.
  107. Shaw AT, Yeap BY, Solomon BJ, Riely GJ, Gainor J, Engelman JA, Shapiro GI, Costa DB, Ou SH, Butaney M, Salgia R, Maki RG, Varella-Garcia M, Doebele RC, Bang YJ, Kulig K, Selaru P, Tang Y, Wilner KD, Kwak EL, Clark JW, Iafrate AJ, Camidge DR. Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis. Lancet Oncol. 2011 Oct; 12(11):1004-12. PMID: 21933749; PMCID: PMC3328296.
  108. Shaw AT, Forcione DG, Digumarthy SR, Iafrate AJ. Case records of the Massachusetts General Hospital. Case 21-2011. A 31-year-old man with ALK-positive adenocarcinoma of the lung. N Engl J Med. 2011 Jul 14; 365(2):158-67. PMID: 21751909.
    View in: PubMed
  109. Sequist LV, Heist RS, Shaw AT, Fidias P, Temel JS, Lennes IT, Bast E, Waltman BA, Lanuti M, Muzikansky A, Mino-Kenudson M, Iafrate AJ, Borger DR, Dias-Santagata D, Engelman JA. SNaPshot genotyping of non-small cell lung cancers (NSCLC) in clinical practice. J Clin Oncol. 2011 May 20; 29(15_suppl):7518. PMID: 28023280.
    View in: PubMed
  110. Shaw AT, Yeap BY, Solomon BJ, Riely GJ, Iafrate AJ, Shapiro G, Costa DB, Butaney M, Ou SI, Maki RG, Bang Y, Varella-Garcia M, Salgia R, Wilner KD, Kulig K, Selaru P, Tang Y, Kwak EL, Clark JW, Camidge DR. Impact of crizotinib on survival in patients with advanced, ALK-positive NSCLC compared with historical controls. J Clin Oncol. 2011 May 20; 29(15_suppl):7507. PMID: 28023300.
    View in: PubMed
  111. Camidge DR, Bang Y, Kwak EL, Shaw AT, Iafrate AJ, Maki RG, Solomon BJ, Ou SI, Salgia R, Wilner KD, Costa DB, Shapiro G, LoRusso P, Stephenson P, Tang Y, Ruffner K, Clark JW. Progression-free survival (PFS) from a phase I study of crizotinib (PF-02341066) in patients with ALK-positive non-small cell lung cancer (NSCLC). J Clin Oncol. 2011 May 20; 29(15_suppl):2501. PMID: 28022383.
    View in: PubMed
  112. Crinò L, Kim D, Riely GJ, Janne PA, Blackhall FH, Camidge DR, Hirsh V, Mok T, Solomon BJ, Park K, Gadgeel SM, Martins R, Han J, De Pas TM, Bottomley A, Polli A, Petersen J, Tassell VR, Shaw AT. Initial phase II results with crizotinib in advanced ALK-positive non-small cell lung cancer (NSCLC): PROFILE 1005. J Clin Oncol. 2011 May 20; 29(15_suppl):7514. PMID: 28023275.
    View in: PubMed
  113. Heist RS, Duda GD, Sahani D, Ancukiewicz M, Fidias P, Sequist LV, Shaw AT, Temel JS, Lennes IT, Neal JW, Pennell NA, Lynch TJ, Engelman JA, Jain RK. Phase II trial of carboplatin, abraxane, and bevacizumab in NSCLC. J Clin Oncol. 2011 May 20; 29(15_suppl):e18016. PMID: 28020106.
    View in: PubMed
  114. Shaw AT, Winslow MM, Magendantz M, Ouyang C, Dowdle J, Subramanian A, Lewis TA, Maglathin RL, Tolliday N, Jacks T. Selective killing of K-ras mutant cancer cells by small molecule inducers of oxidative stress. Proc Natl Acad Sci U S A. 2011 May 24; 108(21):8773-8. PMID: 21555567; PMCID: PMC3102385.
  115. Katayama R, Khan TM, Benes C, Lifshits E, Ebi H, Rivera VM, Shakespeare WC, Iafrate AJ, Engelman JA, Shaw AT. Therapeutic strategies to overcome crizotinib resistance in non-small cell lung cancers harboring the fusion oncogene EML4-ALK. Proc Natl Acad Sci U S A. 2011 May 03; 108(18):7535-40. PMID: 21502504; PMCID: PMC3088626.
  116. Sequist LV, Waltman BA, Dias-Santagata D, Digumarthy S, Turke AB, Fidias P, Bergethon K, Shaw AT, Gettinger S, Cosper AK, Akhavanfard S, Heist RS, Temel J, Christensen JG, Wain JC, Lynch TJ, Vernovsky K, Mark EJ, Lanuti M, Iafrate AJ, Mino-Kenudson M, Engelman JA. Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors. Sci Transl Med. 2011 Mar 23; 3(75):75ra26. PMID: 21430269; PMCID: PMC3132801.
  117. Crystal AS, Shaw AT. New targets in advanced NSCLC: EML4-ALK. Clin Adv Hematol Oncol. 2011 Mar; 9(3):207-14. PMID: 21475126.
    View in: PubMed
  118. Shaw AT, Solomon B. Targeting anaplastic lymphoma kinase in lung cancer. Clin Cancer Res. 2011 Apr 15; 17(8):2081-6. PMID: 21288922.
    View in: PubMed
  119. Neal JW, Shaw AT. One allele's loss is another's gain: alterations of NKX2-8 in non-small cell lung cancer. Clin Cancer Res. 2011 Feb 15; 17(4):638-9. PMID: 21163872; PMCID: PMC3045701.
  120. Ou SH, Bazhenova L, Camidge DR, Solomon BJ, Herman J, Kain T, Bang YJ, Kwak EL, Shaw AT, Salgia R, Maki RG, Clark JW, Wilner KD, Iafrate AJ. Rapid and dramatic radiographic and clinical response to an ALK inhibitor (crizotinib, PF02341066) in an ALK translocation-positive patient with non-small cell lung cancer. J Thorac Oncol. 2010 Dec; 5(12):2044-6. PMID: 21102269.
    View in: PubMed
  121. Kwak EL, Bang YJ, Camidge DR, Shaw AT, Solomon B, Maki RG, Ou SH, Dezube BJ, Jänne PA, Costa DB, Varella-Garcia M, Kim WH, Lynch TJ, Fidias P, Stubbs H, Engelman JA, Sequist LV, Tan W, Gandhi L, Mino-Kenudson M, Wei GC, Shreeve SM, Ratain MJ, Settleman J, Christensen JG, Haber DA, Wilner K, Salgia R, Shapiro GI, Clark JW, Iafrate AJ. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med. 2010 Oct 28; 363(18):1693-703. PMID: 20979469; PMCID: PMC3014291.
  122. Bang Y, Kwak EL, Shaw AT, Camidge DR, Iafrate AJ, Maki RG, Solomon BJ, Ou SI, Salgia R, Clark JW. Clinical activity of the oral ALK inhibitor PF-02341066 in ALK-positive patients with non-small cell lung cancer (NSCLC). J Clin Oncol. 2010 Jun 20; 28(18_suppl):3. PMID: 27937460.
    View in: PubMed
  123. Rodig SJ, Mino-Kenudson M, Dacic S, Yeap BY, Shaw A, Barletta JA, Stubbs H, Law K, Lindeman N, Mark E, Janne PA, Lynch T, Johnson BE, Iafrate AJ, Chirieac LR. Unique clinicopathologic features characterize ALK-rearranged lung adenocarcinoma in the western population. Clin Cancer Res. 2009 Aug 15; 15(16):5216-23. PMID: 19671850; PMCID: PMC2865649.
  124. Shaw AT, Yeap BY, Mino-Kenudson M, Digumarthy SR, Costa DB, Heist RS, Solomon B, Stubbs H, Admane S, McDermott U, Settleman J, Kobayashi S, Mark EJ, Rodig SJ, Chirieac LR, Kwak EL, Lynch TJ, Iafrate AJ. Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK. J Clin Oncol. 2009 Sep 10; 27(26):4247-53. PMID: 19667264; PMCID: PMC2744268.
  125. Shaw AT, Costa D, Mino-Kenudson M, Digumarthy S, Yeap BY, Admane S, Rodig S, Chirieac L, Iafrate AJ, Lynch TJ. Clinicopathologic features of EML4-ALK mutant lung cancer. J Clin Oncol. 2009 May 20; 27(15_suppl):11021. PMID: 27963964.
    View in: PubMed
  126. Lynch TJ, Blumenschein GR, Engelman JA, Espinoza-Delgado I, Govindan R, Hanke J, Hanna NH, Heymach JV, Hirsch FR, Janne PA, Lilenbaum RC, Natale RB, Riely GJ, Sequist LV, Shapiro GI, Shaw A, Shepherd FA, Socinski M, Sorensen AG, Wakelee HA, Weitzman A. Summary statement novel agents in the treatment of lung cancer: Fifth Cambridge Conference assessing opportunities for combination therapy. J Thorac Oncol. 2008 Jun; 3(6 Suppl 2):S107-12. PMID: 18520291.
    View in: PubMed
  127. Shaw, A. T., Tolliday, N., and Jacks, T. Tolperisone and tolperisone-like drugs for the treatment of Kras mutant cancers. 2007.
  128. Shaw AT, Meissner A, Dowdle JA, Crowley D, Magendantz M, Ouyang C, Parisi T, Rajagopal J, Blank LJ, Bronson RT, Stone JR, Tuveson DA, Jaenisch R, Jacks T. Sprouty-2 regulates oncogenic K-ras in lung development and tumorigenesis. Genes Dev. 2007 Mar 15; 21(6):694-707. PMID: 17369402; PMCID: PMC1820943.
  129. Shaw, A. T., Gillette, M. A., Dowdle, J. A., Chang, B., Saenz-Vash, V., Clauser, K., Jaffe, J., Carr, S. A., and Jacks, T. . Biomarker discovery and preclinical validation using mouse models of lung cancer. AACR Meeting Abstracts. 2006; 2006:1350-1.
  130. Shaw AT, Kirsch DG, Jacks T. Future of early detection of lung cancer: the role of mouse models. Clin Cancer Res. 2005 Jul 01; 11(13 Pt 2):4999s-5003s. PMID: 16000603.
    View in: PubMed
  131. Lynch TJ, Bogart JA, Curran WJ, DeCamp MM, Gandara DR, Goss G, Henschke CI, Jett JR, Johnson BE, Kelly KL, Le Chevalier T, Mulshine JL, Scagliotti GV, Schiller JH, Shaw A, Thatcher N, Vokes EE, Wood DE, Hart C. Early stage lung cancer--new approaches to evaluation and treatment: conference summary statement. Clin Cancer Res. 2005 Jul 01; 11(13 Pt 2):4981s-4983s. PMID: 16000599.
    View in: PubMed
  132. Kim CF, Jackson EL, Kirsch DG, Grimm J, Shaw AT, Lane K, Kissil J, Olive KP, Sweet-Cordero A, Weissleder R, Jacks T. Mouse models of human non-small-cell lung cancer: raising the bar. Cold Spring Harb Symp Quant Biol. 2005; 70:241-50. PMID: 16869760.
    View in: PubMed
  133. Gillette, M. A., Chang, B., Saenz-Vash, V., Clauser, K., Jaffe, J., Shaw, A., Jacks, T., and Carr, S. A. Lung cancer biomarker discovery and pre-clinical validation using a mouse model. American Society for Mass Spectometry. 2005.
  134. Tuveson DA, Shaw AT, Willis NA, Silver DP, Jackson EL, Chang S, Mercer KL, Grochow R, Hock H, Crowley D, Hingorani SR, Zaks T, King C, Jacobetz MA, Wang L, Bronson RT, Orkin SH, DePinho RA, Jacks T. Endogenous oncogenic K-ras(G12D) stimulates proliferation and widespread neoplastic and developmental defects. Cancer Cell. 2004 Apr; 5(4):375-87. PMID: 15093544.
    View in: PubMed
  135. Katz, S. G., Williams, A., Yang, J., Fujiwara, Y., Tsang, A. P., Epstein, J. A., and Orkin, S. H. Endothelial lineage-mediated loss of the GATA cofactor Friend of GATA 1 impairs cardiac development. Proc Natl Acad Sci U S A. 2003; 100:14030-14035.
  136. Tsang, A. P., Crispino, J. C., and Orkin, S. H. The role of GATA and FOG proteins in erythroid and megakaryocyte differentiation. Transcription Factors: Normal and Malignant Development of Blood Cells, K. Ravid, and J. D. Licht, eds. 2001; 1-12.
  137. Tsang, A. P. . Identification of FOG, an essential cofactor for transcription factor GATA-1 in hematopoiesis. 1998.
  138. Tsang, A. P., Fujiwara, Y., Hom, D. B., and Orkin, S. H. Failure of megakaryopoiesis and arrested erythropoiesis in mice lacking the GATA-1 transcriptional cofactor FOG. Genes Dev. 1998; 12:1176-1188.
  139. Tsang, A. P., Visvader, J. E., Turner, C. A., Fujiwara, Y., Yu, C., Weiss, M. J., Crossley, M., and Orkin, S. H. . FOG, a multitype zinc finger protein, acts as a cofactor for transcription factor GATA-1 in erythroid and megakaryocytic differentiation. Cell. 1997; 90:109-119.
  140. Tsang, A. P., Fujiwara, Y., Hom, D. B., and Orkin, S. H. The GATA-1 cofactor FOG (friend of GATA-1) is essential for normal erythroid differentiation and megakaryocyte development. Blood. 1997; 90:575.
  141. Tsang, A. P., Visvader, J. E., Turner, C. A., Fujiwara, Y., Crossley, M., and Orkin, S. H. FOG-1 (friend of GATA-1): a candidate cofactor for the transcription factor GATA-1 in erythroid and megakaryocytic lineages. Blood. 1996; 88:553.
  142. Crossley, M., Tsang, A. P., Bieker, J. J., and Orkin, S. H. . Regulation of the erythroid Kruppel-like factor (EKLF) gene promoter by the erythroid transcription factor GATA-1. J Biol Chem. 1994; 269:15440-15444.
  143. Protic, M., Hirschfeld, S., Tsang, A. P., Wagner, M., Dixon, K., and Levine, A. S. . Induction of a novel damage-specific DNA binding protein correlates with enhanced DNA repair in primate cells. Mol Toxicol. 1989; 2006:255-270.
Local representatives can answer questions about the Profiles website or help with editing a profile or issues with profile data. For assistance with this profile: HMS/HSDM faculty should contact feedbackcatalyst.harvard.edu. For faculty or fellow appointment updates and changes, please ask your appointing department to contact HMS. For fellow personal and demographic information, contact HMS Human Resources at human_resourceshms.harvard.edu. For faculty personal and demographic information, contact HMS Office for Faculty Affairs at facappthms.harvard.edu.
Shaw's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts Expand Description
_
Co-Authors Expand Description
_
Similar People Expand Description
_
Same Department Expand Description
Physical Neighbors Expand Description
_